EPCAM and cancer: Using EpCAM to define 4 T1 cancer stemness (Fig. 5l), EpCAM(+) cells were reduced in shMCT-1 (#3–28) mammospheres (65.6%) than in the scramble control (100%), and tocilizumab further decreased the EpCAM(+) populations (28.9%) in the shMCT-1 background.